These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37307533)

  • 1. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
    Yibirin M; Mustafayev K; Hosry J; Pundhir P; Klingen J; Yepez Guevara E; Granwehr BP; Kaseb A; Naing A; Patel S; Shah AY; Skoulidis F; Tawbi HA; Wang L; Miller E; Zhang HC; Zurita-Saavedra A; Torres HA
    Am J Gastroenterol; 2023 Sep; 118(9):1609-1617. PubMed ID: 37307533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Mustafayev K; Mallet V; Torres HA
    J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
    Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
    World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Alkrekshi A; Tamaskar I
    Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
    Yibirin M; Hosry J; Yepez Guevara E; Granwehr BP; Jiang Y; Mustafayev K; Angelidakis G; Torres HA
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1098-1101. PubMed ID: 36062500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N
    Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
    Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
    APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors.
    Smith DE; Chen S; Fargnoli A; Lewis T; Galloway AC; Kon ZN; Moazami N
    Semin Thorac Cardiovasc Surg; 2021; 33(2):407-415. PubMed ID: 32621962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
    Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
    World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
    Sarrazin C; Isakov V; Svarovskaia ES; Hedskog C; Martin R; Chodavarapu K; Brainard DM; Miller MD; Mo H; Molina JM; Sulkowski MS
    Clin Infect Dis; 2017 Jan; 64(1):44-52. PubMed ID: 27737953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
    Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
    World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.